Correlation of ETAR expression with DFST according to clinicopathological variablesa
| Clinicopathological variables . | ETAR status . | DFST . | P b . |
|---|---|---|---|
| . | . | Months (95% CI) . | . |
| Tumor size | |||
| ≤2 cm | Negative | 97 (87–106) | NSc; 0.141 |
| Positive | 82 (66–98) | ||
| Tumor size | |||
| >2 cm | Negative | 82 (69–96) | NS; 0.194 |
| Positive | 67 (51–83) | ||
| Lymph node negative | Negative | 95 (85–104) | NS; 0.424 |
| Positive | 86 (72–101) | ||
| Lymph node positive | Negative | 80 (64–95) | NS; 0.145 |
| Positive | 61 (45–76) | ||
| Invasive ductal | Negative | 88 (77–100) | NS; 0.296 |
| Positive | 74 (60–87) | ||
| Invasive lobular | Negative | 73 (54–92) | NS; 0.331 |
| Positive | 90 (64–115) | ||
| Special | Negative | 105 (94–116) | 0.003 |
| Positive | 62 (40–84) | ||
| Histologic grade I–II | Negative | 96 (87–93) | 0.046 |
| Positive | 78 (64–93) | ||
| Histologic grade III | Negative | 71 (52–91) | NS; 0.837 |
| Positive | 67 (49–86) | ||
| ER positive | Negative | 96 (85–106) | 0.011 |
| Positive | 71 (58–85) | ||
| ER negative | Negative | 76 (63–89) | NS; 0.922 |
| Positive | 75 (54–96) | ||
| PR positive | Negative | 95 (84–106) | NS; 0.090 |
| Positive | 79 (64–95) | ||
| PR negative | Negative | 76 (64–88) | NS; 0.327 |
| Positive | 66 (50–83) | ||
| Her-2/neu negative | Negative | 88 (80–97) | 0.035 |
| Positive | 71 (58–83) | ||
| Her-2/neu positive | Negative | 79 (56–102) | NS; 0.627 |
| Positive | Censored | ||
| MIB-1 labeling index ≤20% | Negative | 92 (82–102) | 0.002 |
| Positive | 64 (50–78) | ||
| MIB-1 labeling index >20% | Negative | 82 (65–99) | NS; 0.503 |
| Positive | 86 (68–104) | ||
| Lymphovascular invasion absent | Negative | 93 (84–101) | 0.033 |
| Positive | 75 (62–88) | ||
| Lymphovascular invasion present | Negative | 65 (41–88) | NS; 0.965 |
| Positive | 66 (44–88) | ||
| No inflammatory component | Negative | 90 (81–99) | NS; 0.059 |
| Positive | 75 (63–86) | ||
| Inflammatory component | Negative | 77 (40–115) | 0.045 |
| Positive | 8 |
| Clinicopathological variables . | ETAR status . | DFST . | P b . |
|---|---|---|---|
| . | . | Months (95% CI) . | . |
| Tumor size | |||
| ≤2 cm | Negative | 97 (87–106) | NSc; 0.141 |
| Positive | 82 (66–98) | ||
| Tumor size | |||
| >2 cm | Negative | 82 (69–96) | NS; 0.194 |
| Positive | 67 (51–83) | ||
| Lymph node negative | Negative | 95 (85–104) | NS; 0.424 |
| Positive | 86 (72–101) | ||
| Lymph node positive | Negative | 80 (64–95) | NS; 0.145 |
| Positive | 61 (45–76) | ||
| Invasive ductal | Negative | 88 (77–100) | NS; 0.296 |
| Positive | 74 (60–87) | ||
| Invasive lobular | Negative | 73 (54–92) | NS; 0.331 |
| Positive | 90 (64–115) | ||
| Special | Negative | 105 (94–116) | 0.003 |
| Positive | 62 (40–84) | ||
| Histologic grade I–II | Negative | 96 (87–93) | 0.046 |
| Positive | 78 (64–93) | ||
| Histologic grade III | Negative | 71 (52–91) | NS; 0.837 |
| Positive | 67 (49–86) | ||
| ER positive | Negative | 96 (85–106) | 0.011 |
| Positive | 71 (58–85) | ||
| ER negative | Negative | 76 (63–89) | NS; 0.922 |
| Positive | 75 (54–96) | ||
| PR positive | Negative | 95 (84–106) | NS; 0.090 |
| Positive | 79 (64–95) | ||
| PR negative | Negative | 76 (64–88) | NS; 0.327 |
| Positive | 66 (50–83) | ||
| Her-2/neu negative | Negative | 88 (80–97) | 0.035 |
| Positive | 71 (58–83) | ||
| Her-2/neu positive | Negative | 79 (56–102) | NS; 0.627 |
| Positive | Censored | ||
| MIB-1 labeling index ≤20% | Negative | 92 (82–102) | 0.002 |
| Positive | 64 (50–78) | ||
| MIB-1 labeling index >20% | Negative | 82 (65–99) | NS; 0.503 |
| Positive | 86 (68–104) | ||
| Lymphovascular invasion absent | Negative | 93 (84–101) | 0.033 |
| Positive | 75 (62–88) | ||
| Lymphovascular invasion present | Negative | 65 (41–88) | NS; 0.965 |
| Positive | 66 (44–88) | ||
| No inflammatory component | Negative | 90 (81–99) | NS; 0.059 |
| Positive | 75 (63–86) | ||
| Inflammatory component | Negative | 77 (40–115) | 0.045 |
| Positive | 8 |